The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-02), Editas Medicine's 9-Day RSI is 72.20.
The industry rank for Editas Medicine's 9-Day RSI or its related term are showing as below:
EDIT's 9-Day RSI is ranked worse than 90.51% of 1422
companies
in the Biotechnology industry
Industry Median: 50.355
vs EDIT: 72.20
Editas Medicine (NAS:EDIT) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Editas Medicine 9-Day RSI Related Terms
EDIT vs SGMT, AUTL, FBRX: 9-Day RSI Comparison
For the Biotechnology subindustry, Editas Medicine's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Editas Medicine 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Editas Medicine's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Editas Medicine's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Editas Medicine (EDIT) has a 9-Day RSI of 72.20 as of Jul. 02, 2026. According to the industry distribution chart, Editas Medicine ranks #1287 out of 1422 companies in the Biotechnology industry, placing it in the top 90.5%.
Is Editas Medicine's 9-Day RSI too high?
Editas Medicine's current 9-Day RSI is 72.20. The Biotechnology industry median 9-Day RSI is 50.36. Editas Medicine's value of 72.20 is 43.4% above this industry median. Based on the distribution chart, Editas Medicine ranks #1287 out of 1422 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Editas Medicine has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Editas Medicine's 9-Day RSI compare to SGMT and AUTL?
According to the Biotechnology industry distribution chart, Editas Medicine ranks #1287 out of 1422 companies for 9-Day RSI. This places Editas Medicine in the lower half of its industry. The industry median 9-Day RSI is 50.36. Editas Medicine's value of 72.20 is 43.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 50.36, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Editas Medicine's current 9-Day RSI of 72.20 is 43.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 50.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Editas Medicine's current 9-Day RSI is 72.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Editas Medicine stock overvalued right now?
Based on GuruFocus' analysis, Editas Medicine (EDIT) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.88, compared to a current price of $3.64 — trading 93.6% above its estimated fair value. The current 9-Day RSI is 72.20 and 43.4% above the Biotechnology industry median of 50.36. Editas Medicine's overall GF Score™ is 51/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Editas Medicine (EDIT), the current 9-Day RSI is 72.20 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Editas Medicine (EDIT) Overvalued in 2026?
Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued.
The current stock price of $3.64 is trading 93.6% above its estimated GF Value™ of $1.88.
GuruFocus considers Editas Medicine to be Significantly Overvalued.
Key valuation signals for EDIT:
9-Day RSI: 72.20
GF Value™: $1.88 vs. price of $3.64 (93.6% above fair value)
Industry Position: 43.4% above the Biotechnology median (#1287 of 1422)
No single metric tells the full story. See the EDIT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
51GF Score
Get the complete analysis for EDIT
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EDIT has been successfully added to your 